Skip to main content

Coyne Terrance P.'s Form 4 filing

Royalty Pharma plc (RPRX) · filed Dec 3, 2025

Accession no.
0001814876-25-000009
Filed
Dec 3, 2025
Trade date
Dec 1, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions. Open-market sales total $2.77M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Coyne Terrance P.CIK 0001814876Officer (EVP & CFO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 1, 2025Class A Ordinary SharesSSaleDisposed−65,832$39.87−$2,624,721.84592,492Indirect
Dec 1, 2025Class A Ordinary SharesSSaleDisposed−3,750$39.87−$149,512.547,260Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

In addition to the holdings of Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 6,448,180 Class A Ordinary Shares. The Reporting Person also holds 1,807,277 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, certain of which are subject to vesting conditions and may, upon vesting, be converted into an equivalent number of Class A Ordinary Shares.

Read the full filing on SEC EDGAR (opens in a new tab)